Diabetes complications

The prognostic impact of the Stress Hyperglycemia Ratio on End‐Stage Renal Disease among patients with Diabetic Kidney Disease

Diabetes Obes MetabPublished Retrospective cohort study

Authors' conclusion

This study observed a U-shaped relationship between SHR and ESRD in patients with DKD. Both very high and very low SHR values correlate with increased risks, highlighting the critical importance of glucose management in chronic diabetes care.

Study context

Population
Patients with Diabetic Kidney Disease (DKD): Cohort 1 from the West China Hospital T2DM-DKD cohort (January 2008-September 2020); Cohort 2 retrospective cohort from Sichuan University Hospital (January 2019-May 2022)Cohort 1
Participants
316 patients
Exposure
Stress Hyperglycemia Ratio (SHR) tertiles: SHR <0.7 and SHR ≥0.94 vs SHR ≥0.7 to <0.94
Outcome
ESRD
Follow-up
Median 42 months (Cohort 1)
Methodological detailstwo cohorts, Cox proportional hazards models adjusted for key confounders
  • Two cohorts
  • Cox proportional hazards models adjusted for key confounders

Main finding

As reported in the abstract

ESRD (Cohort 1) · median follow-up 42 months
Multivariate analysis
Each group vs T2Hazard ratio (95% CI)
T1
1.71(1.01–2.90)
T3
1.93(1.16–3.20)
Developed End-Stage Renal Disease (ESRD), overall
38.6%
Kaplan-Meier: higher ESRD incidence in lowest and highest tertiles vs middle
P < 0.01

Observational data: associations, not effects.

Further findings

OutcomeAdjusted HR (95% CI)
≥30% eGFR decline or ESRD (Cohort 2) · median follow-up 18.6 monthsT1vs T2SHR <0.72.18 (1.15–4.11)
≥30% eGFR decline or ESRD (Cohort 2) · median follow-up 18.6 monthsT3vs T2SHR ≥0.942.68 (1.38–5.23)

Original publication

The prognostic impact of the Stress Hyperglycemia Ratio on End‐Stage Renal Disease among patients with Diabetic Kidney Disease. Diabetes Obes Metab. Published 21 November 2024. doi:10.1111/dom.16056

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.